This makes NS5A polymorphisms fundamentally different from the resistant variants in other DAA target proteins, in particular NS3 protease, where polymorphisms disappear quickly after the discontinuation of a failed treatment [23,26], and closer to polymorphisms in HCV core which were repeatedly shown to associate with the development of HCC [27,28]. The gene discussed is KRAS; the disease is hepatocellular carcinoma.